Hib vaccine conjugate - sanofi pasteur

Drug Profile

Hib vaccine conjugate - sanofi pasteur

Alternative Names: ActHIB; DF-098; Haemophilus influenzae type b conjugate vaccine - sanofi pasteur

Latest Information Update: 06 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi Pasteur
  • Class Conjugate-vaccines; Haemophilus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilus infections

Most Recent Events

  • 31 Oct 2018 Sanofi and Daiichi Sankyo agree to terminate Hib vaccine conjugate in Japan for Haemophilus infections
  • 02 Aug 2010 sanofi pasteur-Daiichi Sankyo Vaccine Co. agrees to terminate its shareholders agreement on October 31, 2010
  • 30 Jul 2010 sanofi pasteur reaches an agreement to acquire sanofi pasteur-Daiichi Sankyo Vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top